INNOVIVA, INC. Revenue from Related Parties
INNOVIVA, INC. (INVA) reported Revenue from Related Parties of $3.10 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-23.
Discontinued › Income Statement › Other Income
us-gaap:RevenueFromRelatedParties · last filed 2018-02-23
- INNOVIVA, INC. revenue from related parties for the quarter ending 2017-12-31 was $2.44M, a 997.30% increase year-over-year.
- INNOVIVA, INC. revenue from related parties for the quarter ending 2017-09-30 was $221.00K, a 0.00% change year-over-year.
- INNOVIVA, INC. revenue from related parties for the quarter ending 2017-06-30 was $221.00K, a 0.00% change year-over-year.
- INNOVIVA, INC. revenue from related parties for the quarter ending 2017-03-31 was $221.00K, a 0.00% change year-over-year.
- INNOVIVA, INC. revenue from related parties for fiscal 2017 was $3.10M, a 250.17% increase from fiscal 2016.
- INNOVIVA, INC. revenue from related parties for fiscal 2016 was $885.00K, a 0.00% change from fiscal 2015.
- INNOVIVA, INC. revenue from related parties for fiscal 2015 was $885.00K, a 18.21% decline from fiscal 2014.
- INNOVIVA, INC. revenue from related parties for fiscal 2014 was $1.08M, a 67.51% decline from fiscal 2013.
| Period end | Revenue from Related Parties 3 month | Revenue from Related Parties 6 month | Revenue from Related Parties 9 month | Revenue from Related Parties 12 month |
|---|---|---|---|---|
| 2017-12-31 | $2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $2.66M derived: sum of 2 quarters · filed 2018-02-23 | $2.88M derived: sum of 3 quarters · filed 2018-02-23 | $3.10M 10-K · filed 2018-02-23 |
| 2017-09-30 | $221.00K 10-Q · filed 2017-11-03 | $442.00K derived: sum of 2 quarters · filed 2017-11-03 | $663.00K 10-Q · filed 2017-11-03 | $885.00K derived: sum of 4 quarters · filed 2018-02-23 |
| 2017-06-30 | $221.00K 10-Q · filed 2017-08-08 | $442.00K 10-Q · filed 2017-08-08 | $664.00K derived: sum of 3 quarters · filed 2018-02-23 | $885.00K derived: sum of 4 quarters · filed 2018-02-23 |
| 2017-03-31 | $221.00K 10-Q · filed 2017-05-05 | $443.00K derived: sum of 2 quarters · filed 2018-02-23 | $664.00K derived: sum of 3 quarters · filed 2018-02-23 | $885.00K derived: sum of 4 quarters · filed 2018-02-23 |
| 2016-12-31 | $222.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $443.00K derived: sum of 2 quarters · filed 2018-02-23 | $664.00K derived: sum of 3 quarters · filed 2018-02-23 | $885.00K 10-K · filed 2018-02-23 |
| 2016-09-30 | $221.00K 10-Q · filed 2017-11-03 | $442.00K derived: sum of 2 quarters · filed 2017-11-03 | $663.00K 10-Q · filed 2017-11-03 | |
| 2016-06-30 | $221.00K 10-Q · filed 2017-08-08 | $442.00K 10-Q · filed 2017-08-08 | ||
| 2016-03-31 | $221.00K 10-Q · filed 2017-05-05 | |||
| 2015-12-31 | $885.00K 10-K · filed 2018-02-23 | |||
| 2014-12-31 | $1.08M 10-K · filed 2017-02-28 | |||
| 2014-03-31 | $270.00K 10-Q · filed 2014-05-07 | $541.00K derived: sum of 2 quarters · filed 2014-05-07 | $956.00K derived: sum of 3 quarters · filed 2014-05-07 | $2.28M derived: sum of 4 quarters · filed 2014-05-07 |
| 2013-12-31 | $271.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $686.00K derived: sum of 2 quarters · filed 2014-03-03 | $2.01M derived: sum of 3 quarters · filed 2014-03-03 | $3.33M 10-K · filed 2014-03-03 |
| 2013-09-30 | $415.00K 10-Q · filed 2013-11-01 | $1.74M derived: sum of 2 quarters · filed 2013-11-01 | $3.06M 10-Q · filed 2013-11-01 | $4.38M derived: sum of 4 quarters · filed 2014-05-07 |
| 2013-06-30 | $1.32M 10-Q · filed 2013-08-01 | $2.64M 10-Q · filed 2013-08-01 | $3.97M derived: sum of 3 quarters · filed 2014-05-07 | $5.40M derived: sum of 4 quarters · filed 2014-05-07 |
| 2013-03-31 | $1.32M 10-Q · filed 2014-05-07 | $2.64M derived: sum of 2 quarters · filed 2014-05-07 | $4.07M derived: sum of 3 quarters · filed 2014-05-07 | $5.50M derived: sum of 4 quarters · filed 2014-05-07 |
| 2012-12-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $2.75M derived: sum of 2 quarters · filed 2014-03-03 | $4.18M derived: sum of 3 quarters · filed 2014-03-03 | $5.61M 10-K · filed 2014-03-03 |
| 2012-09-30 | $1.43M 10-Q · filed 2013-11-01 | $2.86M derived: sum of 2 quarters · filed 2013-11-01 | $4.29M 10-Q · filed 2013-11-01 | $6.65M derived: sum of 4 quarters · filed 2014-03-03 |
| 2012-06-30 | $1.43M 10-Q · filed 2013-08-01 | $2.86M 10-Q · filed 2013-08-01 | $5.22M derived: sum of 3 quarters · filed 2014-03-03 | $7.60M derived: sum of 4 quarters · filed 2014-03-03 |
| 2012-03-31 | $1.43M 10-Q · filed 2013-05-01 | $3.79M derived: sum of 2 quarters · filed 2014-03-03 | $6.17M derived: sum of 3 quarters · filed 2014-03-03 | $8.63M derived: sum of 4 quarters · filed 2014-03-03 |
| 2011-12-31 | $2.36M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $4.74M derived: sum of 2 quarters · filed 2014-03-03 | $7.20M derived: sum of 3 quarters · filed 2014-03-03 | $9.66M 10-K · filed 2014-03-03 |
| 2011-09-30 | $2.38M 10-Q · filed 2012-10-31 | $4.84M derived: sum of 2 quarters · filed 2012-10-31 | $7.29M 10-Q · filed 2012-10-31 | |
| 2011-06-30 | $2.46M 10-Q · filed 2012-08-01 | $4.91M 10-Q · filed 2012-08-01 | ||
| 2010-12-31 | $9.83M 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |